Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells

Molecular Therapy

Volumn 17, Issue 11, 2009, Pages 1910-1918

  Bosticardo, Marita ^a   Ghosh, Amrita ^a   Du, Yang ^b,c   Jenkins, Nancy A ^b   Copeland, Neal G ^b   Candotti, Fabio ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN EVI1; PROTEIN HOXA7; PROTEIN MDS1; PROTEIN MEF2C; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE MARROW CULTURE; CELL IMMORTALIZATION; CONTROLLED STUDY; ENHANCER REGION; GENE DELETION; GENE INACTIVATION; GENE INSERTION; GENE TRANSFER; GENETIC TRANSDUCTION; LONG TERMINAL REPEAT; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; ONCOGENE; PROMOTER REGION;

ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; GENE THERAPY; GENETIC VECTORS; MICE; MOLONEY MURINE LEUKEMIA VIRUS; MUTAGENESIS, INSERTIONAL; PROMOTER REGIONS, GENETIC; RETROVIRIDAE; TERMINAL REPEAT SEQUENCES; TRANSDUCTION, GENETIC; VIRUS INTEGRATION;

ANIMALIA; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE;

EID: 70449084880     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.172     Document Type: Article

References (32)

1. Stocking, C, Bergholz, U, Friel, J, Klingler, K, Wagener, T, Starke, C et al. (1993). Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line. Growth Factors 8: 197-209.
2. Moolten, FL and Cupples, LA (1992). A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum Gene Ther 3 479-486.
3. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
4. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
5. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
6. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
7. Li, Z, Dullmann, J, Schiedlmeier, B, Schmidt, M, von Kalle, C, Meyer, J et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
8. Kustikova, O, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174.
9. Modlich, U, Kustikova, OS, Schmidt, M, Rudolph, C, Meyer, J, Li, Z et al. (2005). Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105: 4235-4246.
10. Yu, SF, von Rüden, T, Kantoff, PW, Garber, C, Seiberg, M, Rüther, U et al. (1986). Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 83: 3194-3198.
11. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knöss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553.
12. Du, Y, Jenkins, NA and Copeland, NG (2005). Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106: 3932-3939.
13. McBurney, MW, Sutherland, LC, Adra, CN, Leclair, B, Rudnicki, MA and Jardine, K (1991). The mouse Pgk-1 gene promoter contains an upstream activator sequence. Nucleic Acids Res 19: 5755-5761.
14. Julius, MA, Yan, Q, Zheng, Z and Kitajewski, J (2000). Q vectors, bicistronic retroviral vectors for gene transfer. BioTechniques 28: 702-708.
15. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
16. Akagi, K, Suzuki, T, Stephens, RM, Jenkins, NA and Copeland, NG (2004). RTCGD: Retroviral tagged cancer gene database. Nucleic Acids Res 32(Database issue): D523-D527.
17. Buonamici, S, Chakraborty, S, Senyuk, V and Nucifora, G (2003). The role of EVI1 in normal and leukemic cells. Blood Cells Mol Dis 31 206-212.
18. Phan, RT and Dalla-Favera, R (2004). The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432: 635-639.
19. Sawka-Verhelle, D, Escoubet-Lozach, L, Fong, AL, Hester, KD, Herzig, S, Lebrun, P et al. (2004). PE-1/METS, an antiproliferative Ets repressor factor, is induced by CREB-1/CREM-1 during macrophage differentiation. J Biol Chem 279: 17772-17784.
20. Suzuki, T, Shen, H, Akagi, K, Morse, HC, Malley, JD, Naiman, DQ et al (2002). New genes involved in cancer identified by retroviral tagging. Nat Genet 32: 166-174.
21. Eklund, EA (2007). The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 14: 85-89.
22. Du, Y, Spence, SE, Jenkins, NA and Copeland, NG (2005). Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 106: 2498-2505.
23. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725.
24. Cornils, K, Lange, C, Schambach, A, Brugman, MH, Nowak, R, Lioznov, M et al. (2009). Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol Ther 17: 131-143.
25. Kraunus, J, Schaumann, DH, Meyer, J, Modlich, U, Fehse, B, Brandenburg, G et al. (2004). Self-inactivating retroviral vectors with improved RNA processing. Gene Ther 11: 1568-1578.
26. Taveau, M, Stockholm, D, Marchand, S, Roudaut, C, Le Bert, M and Richard, I (2004). Bidirectional transcriptional activity of the Pgk1 promoter and transmission ratio distortion in Capn3-deficient mice. Genomics 84: 592-595.
27. Scacheri, PC, Crabtree, JS, Novotny, EA, Garrett-Beal, L, Chen, A, Edgemon, KA et al. (2001). Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis 30: 259-263.
28. Calmels, B, Ferguson, C, Laukkanen, MO, Adler, R, Faulhaber, M, Kim, HJ et al. (2005). Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106 2530-2533.
29. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
30. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
31. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
32. Otsu, M, Anderson, SM, Bodine, DM, Puck, JM, O'Shea, JJ and Candotti, F (2000). Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol Ther 1 145-153.